병원약사회지

  • 자료실
  • 병원약사회지
[논문] 비전이성 유방암 수술환자의 보조화학요법 현황(Utilization of Adjuvant Chemotherapy in Patients with Non-Metastatic Breast Cancer after Surgery)
Date

2021년 Vol.38 No.02

Authors
구민희a,b, 제남경a†(부산대학교 약학대학 약물사용연구실a, 동남권원자력의학원 약제실b)
Keyword
Breast cancer, Adjuvant chemotherapy, Mastectomy, Breast-conserving surgery
Abstract

Background : In July 2017, breast cancer surgery codes have been revised to more accurately describe a procedure of breast cancer surgery. This study aimed to investigate the current practice patterns of breast cancer surgery and the subsequent adjuvant chemotherapy after the revision of breast cancer surgery codes.


Methods : We analyzed the 2018 inpatient datasets provided by the Health Insurance Review and Assessment Service (HIRA-NIS-2018-0047). Female patients with non-metastatic breast cancer who underwent breast cancer surgery and adjuvant chemotherapy were selected. Multinomial logistic regression analysis was performed to explore the relationships among variables regarding the selection of adjuvant chemotherapy relative to the doxorubicin and cyclophosphamide (AC) regimen.


Results : Breast-conserving surgery was performed more frequently than mastectomy (70.2% vs. 29.8%) in 2018. For study subjects who underwent axillary lymph node dissection, the odds ratio for selecting sequential anthracycline-cyclophosphamide and taxane (AC-T) as adjuvant chemotherapy over AC was 23.27 (95% confidence interval [CI]=8.61-62.91). For patients aged 65 years or older, the odds ratio for selecting cyclophosphamide, methotrexate, and 5-Fluorouracil (CMF) as adjuvant chemotherapy over AC was 12.16 (95% CI=3.22-46.00).


Conclusion : Factors influencing the choice of adjuvant chemotherapy were associated with age and presence of positive lymph nodes.



Full-Text
171-184학술보고2구민희.pdf